SUBSCRIBE
SUBSCRIBE
Pharm Country

Drug for RSV Linked to Shorter Hospital Stays, Albert Einstein College of Medicine Study

May 3, 2010 | 
1 min read

MedPage Today -- VANCOUVER -- The monoclonal antibody palivizumab (Synagis) appears to be associated with a marked reduction in length of hospital stay for respiratory syncytial virus, a researcher said here.

MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Mother covering her face, experiencing depression symptoms
Drug Development
Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial
May 3, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Business
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
April 29, 2024
 · 
2 min read
 · 
Tyler Patchen